 | Up a level |
Journal Article
Abbas, M., Daemmrich, M. E., Braubach, P., Kramer, M. W., Gruenwald, V., Merseburger, A. S., Herrmann, T. R. W., Becker, J. U. and Kreipe, H. H. (2015). Role of immunohistochemistry and fluorescence in-situ hybridization (FISH) in the diagnosis of spindle and round cell tumors of the kidney. J. Egypt. Natl. Cancer Inst., 27 (3). S. 173 - 179. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1687-9996
Baretton, G., Dietel, M., Gaiser, T., Kirchner, T., Kreipe, H. H., Quaas, A., Roecken, C., Rueschoff, J., Tannapfel, A., Lordick, F., Al-Batran, S., Hofheinz, R., Lorenzen, S., Moehler, M. and Thuss-Patience, P. (2016). HER2 testing in gastric cancer. Results of ameeting of German experts. Pathologe, 37 (4). S. 361 - 367. NEW YORK: SPRINGER. ISSN 1432-1963
Gluz, O., Kreipe, H. H., Kates, R. E., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Salem, M., Liedtke, B., Aktas, B., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U. and Harbeck, N. (2012). Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Gluz, O., Nitz, U., Christgen, M., Malter, W., Clemens, M., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Ppllmanns, A., Lorenz-Salehi, F., Uleer, C., Krabisch, P., Kuemmel, S., Liedtke, C., Shak, S., Kates, R., Wurstlein, R., Kreipe, H. H. and Harbeck, N. (2017). Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Gluz, O., Nitz, U., Kreipe, H. H., Christgen, M., Kates, R. E., Hofmann, D., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., Kusche, M., Heyl, V., Lorenz-Salehi, F., Just, M., Liedtke, C., Wuerstlein, R. and Harbeck, N. (2015). Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX (R): First prospective survival results from the WSG phase III planB trial. Eur. J. Cancer, 51. S. S311 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Harbeck, N., Gluz, O., Christgen, M., Braun, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., de Haas, S. L., Kiermaier, A., Kreipe, H. H. and Nitz, U. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Harbeck, N., Gluz, O., Kreipe, H. H., Christgen, M., Svedman, C., Shak, S., Hofmann, D., Kuemmel, S., Nuding, B., Rezai, M., Schumacher, C., Kusche, M., Forstbauer, H., Maass, N., Kraemer, S., Aktas, B., Mohrmann, S., Wuerstlein, R., Kates, R. E. and Nitz, U. (2013). Run-in phase of prospective WSG-ADAPT HR+/ HER2-trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Harbeck, N., Nitz, U. A., Matthias, C., Kates, R., Braun, M., Kummel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Grischke, E-M, de Haas, S. L., Deurloo, R., Schumacher, J., Wuerstlein, R., Kreipe, H. H. and Gluz, O. (2017). The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC). Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Huober, J., Gluz, O., Hartmann, A., Kates, R., Kreipe, H. H., Pelz, E., Thomssen, C., Fischer, H. H., Moebus, V., Augustin, D., Weiss, E., Erber, R., Liedtke, C., Kuhn, W., Nitz, U. and Harbeck, N. (2010). Evidence for Predictive and Prognostic Impact of Molecular Classification in Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer An Analysis of the WSG EC-Doc Trial. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Liedtke, C., Gluz, O., Heinisch, F., Feuerhake, F., Kreipe, H. H., Clemens, M., Nuding, B., Kraemer, S., Reimer, T., Svedman, C., Shak, S., Nitz, U., Kates, R. E., Harbeck, N. and Christgen, M. (2016). Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) A translational analysis of the prospective WSG planB trial. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Lordick, F., Al-Batran, S. E., Hofheinz, R. D., Lorenzen, S., Thuss-Patience, P., Baretton, G. B., Dietel, M., Gaiser, T., Kirchner, T., Kreipe, H. H., Quaas, A., Roecken, C., Rueschoff, J. and Tannapfel, A. (2016). HER2 testing in gastric cancer - results of a German expert meeting. Z. Gastroent., 54 (8). S. 791 - 797. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-7803